Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01490086 · ClinicalTrials.gov registry record · Phase 2
RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder
A Phase 2 study, sponsored by Reviva Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 234
- Enrollment target
NCT01490086 is a Phase 2 study that has completed, run by Reviva Pharmaceuticals. The registered enrollment target is 234 participants.
The verdict
NCT01490086, a Phase 2 study, has completed, sponsored by Reviva Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 234 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the efficacy and safety of RP5063 relative to placebo for the treatment of schizophrenia or schizoaffective disorder.
Interventions
- DRUG placebo
- DRUG aripiprazole
- DRUG RP5063
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 234 participants |
| Start Date | 2011-12 |
| Est. Completion | 2013-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01490086
The ClinicalTrials.gov registry entry for NCT01490086 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 234 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Reviva Pharmaceuticals, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT01490086 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01490086 about?
NCT01490086 is a clinical study titled "RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder". The objective of this study is to evaluate the efficacy and safety of RP5063 relative to placebo for the treatment of schizophrenia or schizoaffective disorder.
What is the current status of trial NCT01490086?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 234 participants. The study started on 2011-12. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01490086?
The interventions under investigation include: placebo (DRUG), aripiprazole (DRUG), RP5063 (DRUG).
Who is sponsoring clinical trial NCT01490086?
This trial is sponsored by Reviva Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.